Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683535 · ClinicalTrials.gov registry record
Adverse Events Related to Low Dose Atropine
A clinical trial of Myopia, Progressive, sponsored by Scripps Health.
- Completed
- Registry status
- 148
- Enrollment target
- 1
- Study location
NCT05683535: Completed study of Myopia, Progressive, sponsored by Scripps Health.
NCT05683535 is a study of Myopia, Progressive that has completed, run by Scripps Health. The registered enrollment target is 148 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05683535, a study of Myopia, Progressive, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers. The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.
Conditions Studied
Interventions
- DRUG Atropine Sulfate
Study Locations (1)
California
- Laura Kirkeby - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2023-01-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683535
The ClinicalTrials.gov registry entry for NCT05683535 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 1 intervention - of which Atropine Sulfate is the first listed.
NCT05683535 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05683535 about?
NCT05683535 is a clinical study titled "Adverse Events Related to Low Dose Atropine". Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye dr...
What is the current status of trial NCT05683535?
This trial is currently completed. The enrollment target is 148 participants. The study started on 2018-06-19. Estimated completion is 2023-01-09.
What conditions does trial NCT05683535 study?
This clinical trial studies the following conditions: Myopia, Progressive.
What interventions are being tested in trial NCT05683535?
The interventions under investigation include: Atropine Sulfate (DRUG).
Who is sponsoring clinical trial NCT05683535?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683535 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia, Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.